The CD57+/CD57− ratio was about four-fold higher in tumor-rich vs. tumor-sparse regions (4% vs. 17%), indicating that these enriched late T-cell subsets play a role in MCL immunity. The gene discussed is B3GAT1; the disease is neoplasm.